Duda, Dan, DMD, PhD

Duda
Phone:
Email:

Dan G. Duda obtained his DMD from the University of Medicine Iasi, Romania in 1993, and earned his PhD in Medical Sciences (GI Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan in 2001. After graduation, he joined as a Postdoctoral Fellow the Steele Laboratories for Tumor Biology in the Department of Radiation Oncology at Massachusetts General Hospital and Harvard Medical School in Boston. After becoming junior Faculty member (Instructor) in 2004, he rose through the ranks to Associate Professor of Tumor Biology in 2012.
His current research efforts focus on the role of the interactions between locally derived stroma (tumor-associated vessels, fibroblasts) and distant stroma (inflammatory cells) with cancer cells in tumor progression and resistance to treatment. The goal is to identify new targets for therapy and biomarkers of response in translational studies, particularly in intractable cancers. He has authored over 160 publications so far, of which 92 are original reports, including articles in Nature, Nature Genetics, Nature Medicine, Cell, Cancer Cell, PNAS and Journal of Clinical Oncology. He has been invited to present these studies at over 120 local, national and international meetings, including as plenary speaker and keynote speaker.
For his work, Dr. Duda received several awards from the AACR, CRI, IASGO and MGH. He is an Honorary Member of the Academy of Medical Sciences of Romania since 2012. He has served as a panel member for multiple scientific expert meetings worldwide. His research is currently supported by grants from the US National Cancer Institute, Massachusetts General Hospital ECOR, Andrew L. Warshaw, MD, Institute for Pancreatic Cancer and The Samuel Singer Brown Fund for Pancreatic Ductal Adenocarcinoma Research, as well as by partnerships with Industry (Merrimack Pharma, Bayer and HealthCare Pharma). He is the Head of the IASGO Cancer Research Section since 2013, and the Secretary General of the IASGO since 2015. In 2016, he was appointed as the Director of Translational Research in GI Cancer in the Department of Radiation Oncology at MGH Cancer Center. (See full CV below.)

Duda_Full_CV.pdf

Selected Publications (from total of 145)

Hato T, Zhu AX, Duda DG
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Immunotherapy. 2016;8(3):299-313 - PMID: 26865127
Han HS, Niemeyer E, Huang Y, Kamoun WS, Martin JD, Bhaumik J, Chen Y, Roberge S, Cui J, Martin MR, Fukumura D, Jain RK, Bawendi MG, Duda DG
Quantum dot/antibody conjugates for in vivo cytometric imaging in mice.
Proc Natl Acad Sci U S A. 2015;112(5):1350-5 - PMID: 25605916 - PMCID: PMC4321304
Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG
CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice
Hepatology. 2014;61(5):1591-602 - PMID: 25529917 - PMCID: PMC4406806
Duda DG, Ancukiewicz M, Isakoff SJ, Krop IE, Jain RK
Seeds and soil: unraveling the role of local tumor stroma in distant metastasis.
J Natl Cancer Inst. 2014;106(8):ePub - PMID: 25082335
Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG
A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma.
Int J Radiat Oncol Biol Phys. 2014;89(4):830-8 - PMID: 24867540 - PMCID: PMC4791180
Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG
Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1a/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice.
Hepatology. 2013;59(4):1435-47 - PMID: 24242874 - PMCID: PMC3966948
Chan-On W, Nairism├Ągi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
Nat Genet. 2013;45(12):1474-8 - PMID: 24185513
Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, Jackson McCleary N, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG
Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study.
Clin Cancer Res. 2013;19(6):1557-66 - PMID: 23362324 - PMCID: PMC3609423
Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.
Oncologist. 2012;17(2):212-9 - PMID: 22302227 - PMCID: PMC3286170
Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Clin Cancer Res. 2011;17(8):2074-80 - PMID: 21349998 - PMCID: PMC3079023
Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK
Malignant cells facilitate lung metastasis by bringing their own soil.
Proc Natl Acad Sci U S A. 2010;107(50):21677-82 - PMID: 21098274 - PMCID: PMC3003109
Duda DG, Jain RK, Willett CG
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.
J Clin Oncol. 2007;25(26):4033-42 - PMID: 17827451 - PMCID: PMC2686120
12